Elafibranor
- Generic Name
- Elafibranor
- Brand Names
- Iqirvo
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24O4S
- CAS Number
- 923978-27-2
- Unique Ingredient Identifier
- 2J3H5C81A5
- Background
Elafibranor (code name GFT505) is a multimodal and pluripotent medication for treatment of atherogenic dyslipidemia for an overweight patient with or without diabetes. It is an oral treatment that acts on the 3 sub-types of PPAR (PPARa, PPARg, PPARd) with a preferential action on PPARa. As of February 2016, elafibranor has completed 8 clinical trials and a phase III is in progress.
- Indication
Investigated for use/treatment in atherosclerosis and diabetes mellitus type 2.
- Associated Conditions
- -
- Associated Therapies
- -
No trials found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath